Drug Woes Clearing Path For Pharmacogenomics Growth
After a disappointing year for pharmaceutical companies, the Vioxx heat thrown on the FDA, and the withdrawal of Biogen Idec Inc.'s Tysabri, dissecting the drug development model and insinuating pharmacogenomics into it not only is timely, but appropriate.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST